FDA has decided not to send letters to companies calling for submission of data on off-label uses of their products. The agency was on the verge of sending the letters out a few weeks ago, almost a year after they were first mentioned ("The Pink Sheet" May 11, 1992, p. 11), but now feels that it would be inundated with information from firms. FDA is instead planning to send letters to medical specialty groups asking them about unapproved uses for marketed drug products.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth